Sugi Predict

Sugi Predict / Compounds / Antipain

Antipain

Antipain

SCHEMBL5966873

CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(=O)NC(C=O)CCCNC(=N)N

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.74
▸ CTSK P43235 3/20 0.52
▸ CTSB P07858 1/20 0.45
▸ NPY4R P50391 6/20 0.43
▸ NPY1R P25929 4/20 0.43
▸ NPY2R P49146 3/20 0.43
▸ NPY5R Q15761 3/20 0.43
▸ KISS1R Q969F8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Antipain SCHEMBL23132673 1.00 SMN1; SMN2 (0.74) SMN1; SMN2CTSKCTSBNPY4RNPY1R
Antipain SCHEMBL18328611 1.00 SMN1; SMN2 (0.74) SMN1; SMN2CTSKCTSBNPY4RNPY1R
Antipain SCHEMBL14038024 1.00 SMN1; SMN2 (0.74) SMN1; SMN2CTSKCTSBNPY4RNPY1R
Antipain SCHEMBL3280675 1.00 SMN1; SMN2 (0.74) SMN1; SMN2CTSKCTSBNPY4RNPY1R
Antipain SCHEMBL642095 1.00 SMN1; SMN2 (0.74) SMN1; SMN2CTSKCTSBNPY4RNPY1R
SCHEMBL26807763 0.97 SMN1; SMN2 (0.69) SMN1; SMN2CTSKCTSBNPY4RNPY1R
SCHEMBL17364033 0.97 SMN1; SMN2 (0.69) SMN1; SMN2CTSKCTSBNPY4RNPY1R
SCHEMBL16328962 0.93 SMN1; SMN2 (0.65) SMN1; SMN2CTSKCTSBNPY4RNPY1R
SCHEMBL17364037 0.93 SMN1; SMN2 (0.64) SMN1; SMN2CTSKNPY4RNPY1RNPY2R
SCHEMBL17364024 0.93 SMN1; SMN2 (0.64) SMN1; SMN2CTSKNPY4RNPY1RNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060205650-A1 Treatment of neuropsychiatric disease with protease and neuraminidase inhibitors VAWTER MARQUIS P 2006-09-14 — — US disclosed
US-20030211545-A1 Treatment of neuropsychiatric disease with protease and neurominidase inhibitors VAWTER, MARQUIS 2003-11-13 — — US disclosed
WO-2001054729-A1 TREATMENT OF NEUROPSYCHIATRIC DISEASE WITH PROTEASE AND NEURAMINIDASE INHIBITORS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, ASREPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2001-08-02 — — WO disclosed
Send feedback